OX640: Shaping the future of nasal powder epinephrine using the innovative amorphOX platform
Orexo is breaking new ground in the area of anaphylaxis with OX640, an innovative nasal powder epinephrine product. In this interview, Robert Rönn, SVP and Head of Research and Development at Orexo, shares the OX640 clinical study results, why FDA approval is expected, and the far-reaching benefits for patients and prescribers. Is there a need for a new anaphylaxis treatment? Yes, anaphylaxis is a serious allergic reaction that progresses very quickly, and if it isn’t treated, it can be fatal. It affects approximately 26 million adult Americans[1] which is why we set out to